Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovering moderate-risk breast cancer susceptibility genes.
Hollestelle A, Wasielewski M, Martens JW, Schutte M. Hollestelle A, et al. Among authors: martens jw. Curr Opin Genet Dev. 2010 Jun;20(3):268-76. doi: 10.1016/j.gde.2010.02.009. Epub 2010 Mar 24. Curr Opin Genet Dev. 2010. PMID: 20346647 Review.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Hollestelle A, et al. Among authors: martens jw. Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11. Breast Cancer Res Treat. 2010. PMID: 19593635
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Hollestelle A, et al. Among authors: martens jw. Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30. Breast Cancer Res Treat. 2011. PMID: 20676756 Free PMC article.
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. Paranjape T, et al. Among authors: martens jw. Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Lancet Oncol. 2011. PMID: 21435948 Free PMC article.
Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van I Jcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H. Nagel JH, et al. Among authors: martens jw. Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26. Breast Cancer Res Treat. 2012. PMID: 21614566
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
Riaz M, Berns EM, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look MP, Klijn JG, Sleijfer S, Foekens JA, Martens JW. Riaz M, et al. Among authors: martens jw. Breast Cancer Res Treat. 2012 Jun;133(3):843-51. doi: 10.1007/s10549-011-1663-3. Epub 2011 Jul 12. Breast Cancer Res Treat. 2012. PMID: 21748294
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.
Warren H, Dudbridge F, Fletcher O, Orr N, Johnson N, Hopper JL, Apicella C, Southey MC, Mahmoodi M, Schmidt MK, Broeks A, Cornelissen S, Braaf LM, Muir KR, Lophatananon A, Chaiwerawattana A, Wiangnon S, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Sawyer EJ, Tomlinson I, Kerin M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Laurent-Puig P, Mulot C, Bojesen SE, Nielsen SF, Flyger H, Nordestgaard BG, Milne RL, Benítez J, Arias-Pérez JI, Zamora MP, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Brenner H, Müller H, Arndt V, Langheinz A, Meindl A, Golatta M, Bartram CR, Schmutzler RK, Brauch H, Justenhoven C, Brüning T; GENICA Network; Chang-Claude J, Wang-Gohrke S, Eilber U, Dörk T, Schürmann P, Bremer M, Hillemanns P, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Antonenkova N, Rogov Y, Bermisheva M, Prokofyeva D, Zinnatullina G, Khusnutdinova E, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Hartikainen JM, Kataja V, Chenevix-Trench G, Beesley J, Chen X; kConFab Investigators; Australian Ovarian Cancer Study Group; Lambrechts D, Smeets A, Paridaens R, Weltens C, Flesch-Janys D, Buck K, Behrens S, Peterlongo P, Bernard L, Manoukian S… See abstract for full author list ➔ Warren H, et al. Among authors: martens jw. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1783-91. doi: 10.1158/1055-9965.EPI-12-0526. Epub 2012 Aug 2. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22859399 Free PMC article.
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.
Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, Westenend PJ, Heine AA, Chan A, Sieuwerts AM, Wiemer EA, Klijn JG, van der Spek PJ, Foekens JA, Schutte M, den Bakker MA, Martens JW. Hollestelle A, et al. Among authors: martens jw. Breast Cancer Res Treat. 2013 Feb;138(1):47-57. doi: 10.1007/s10549-013-2415-3. Epub 2013 Jan 22. Breast Cancer Res Treat. 2013. PMID: 23338761
416 results